Medicare Prescription Drug Plans 2027: The Coverage Gaps

There is a specific type of anxiety that hits retirees during the annual open enrollment period. It is not just about the premium on the statement. It is the quiet fear that the medication keeping you alive might suddenly vanish from your plan’s formulary. For Medicare Part D beneficiaries, 2027 looks different from 2026, and the differences are subtle but expensive. The standard out-of-pocket threshold is climbing to $2,400, and the maximum deductible is rising to $700. These numbers matter because they define the ceiling of what you pay before Medicare starts covering the rest. But the floor of what you can access is also shifting, and not always in your favor.

The question on everyone’s mind is whether their current prescription drug plan will still cover their specific medications next year. The answer is often no, or at least not in the same way. Plans are adjusting their networks, tiers, and restrictions in response to new regulations and cost pressures. If you have been on the same plan for a decade, you are carrying a blind spot. You assume continuity, but the market is fragmented. This analysis looks past the headline premium increases to examine the structural changes in how Part D works in 2027, specifically for those managing chronic conditions like diabetes, asthma, and heart disease.

The Cost Ceiling Is Rising

The most concrete change for 2027 is the increase in the maximum out-of-pocket limit. According to recent projections, this cap is moving from $2,100 in 2026 to $2,400 in 2027. This is the amount you can spend on covered prescriptions in a year before you no longer pay anything for covered drugs. It sounds like a relief, but the path to getting there is getting steeper. The deductible is also increasing, jumping from $615 to $700. That means you have to pay more upfront before you even start accumulating progress toward that cap.

For a beneficiary with multiple chronic conditions, this math is unforgiving. Consider a hypothetical 66-year-old managing type 2 diabetes and asthma. If they rely on an inhaler that costs $400 a month, the cost structure under a standard plan with a $700 deductible and 25% coinsurance can generate over $1,700 in annual out-of-pocket spending. This is before you even hit the cap. The premium for the plan itself is also part of the equation. While the average stand-alone Part D premium is projected to rise by less than a dollar a month, that is an average. Your specific plan, based on your location and risk profile, could see a different adjustment. The key takeaway is that the safety net is getting higher, but the ladder to reach it is getting longer.

The GLP-1 Complication

No topic is generating more confusion and frustration than the status of GLP-1 medications like Wegovy and Zepbound. There is a hard line in the sand set by a 2003 federal law: Part D cannot cover drugs prescribed solely for weight loss. This creates a bifurcated system that catches many beneficiaries off guard. If your doctor prescribed one of these drugs for cardiovascular risk reduction or for moderate to severe obstructive sleep apnea, you may still qualify for standard Part D coverage. But if the primary indication is weight management, you are excluded from the regular formulary benefits.

To bridge this gap, CMS launched the Medicare GLP-1 Bridge in July 2026. This program offers a flat $50 per prescription, which amounts to $600 a year, for eligible weight management drugs. This is a significant discount compared to cash prices, but it is not free. It ends in December 2027, creating a temporary solution for a permanent problem. For those who lost employer coverage for these drugs, the transition to Medicare is not a seamless swap. It is a complex negotiation of diagnoses and plan rules. You need to verify with your plan whether your specific diagnosis qualifies for the standard benefit or if you are pushed into the Bridge. The distinction matters for your annual budget and your pharmacy experience.

Formulary Volatility

A common misconception is that if a drug is covered this year, it will be covered next year. That is not how the market works. Part D plans update their formularies annually, and 2027 may bring more volatility than usual as insurers adjust to Inflation Reduction Act reforms. Some retirees might see lower costs for certain drugs, but others will encounter narrower formularies or higher tiers. A drug that was on Tier 1 this year could move to Tier 3 next year, drastically increasing your coinsurance. This is why the five prescription details highlighted by experts deserve a second look. You need to check the specific formulary for your plan, not just the general marketing materials.

The risk is not just about price. It is about access. Some plans are adding new coverage restrictions, such as prior authorization requirements or step therapy mandates. These administrative hurdles can delay your access to medication. For a senior with a tight budget, a two-week delay in filling a critical prescription can be a medical crisis. The advice is clear: do not assume your plan will stay the same. Review the 2027 formulary guide that your plan will provide. Look for your specific drugs. Check the tier. Check the restrictions. If your drug is moving to a higher tier, you have the right to switch plans during open enrollment. You can choose a plan that keeps your medication on a lower tier, even if the premium is slightly different. The goal is to minimize your total out-of-pocket cost, not just your monthly premium.

The Employer Coverage Cliff

For those transitioning from employer-sponsored care to Medicare, the gap can be jarring. Some large employers, including Walmart, are changing their benefits for 2027. Walmart announced that its 2027 health plans will make more than 250 prescription medications available at no charge to current employees. This includes GLP-1 drugs, insulin, and inhalers. However, this benefit does not extend to former employees once they transition to Medicare. This creates a stark contrast. A 66-year-old Walmart associate managing diabetes and asthma could pay nothing for their prescriptions while on the payroll. Upon retiring and enrolling in Medicare Part D, that same person could face the full $2,400 out-of-pocket ceiling, plus premiums, depending on their plan.

This disparity highlights a structural flaw in the transition process. The employer plan is designed for a working population with different cost structures. The Medicare plan is designed for a broader, older population with different risk profiles. When you lose the employer benefit, you are not just losing a discount. You are losing a specific coverage model that may have been tailored to your needs. The five variables that determine your cost are the formulary placement, the deductible, the coinsurance rate, the pharmacy network, and whether the drug is covered at all. You need to evaluate these variables for your specific 2027 plan choice. Do not let the convenience of a familiar pharmacy override the financial reality of your new coverage. Compare the total annual cost, not just the monthly premium.

Action Steps for Beneficiaries

The open enrollment period for 2027 plans is running from October 15 through December 7. This is your window to make changes. If you are staying on your current plan, you are essentially betting that nothing will change. That is a risky bet. Use this time to audit your coverage. Check if your drugs are still on the formulary. Check if the tier has changed. Check if there are new prior authorization requirements. If you are considering a switch, look at the total out-of-pocket cost for your specific medications. The lowest premium is not always the best deal. A plan with a higher premium but a lower deductible and a better formulary placement for your drugs might save you more money in the long run.

Remember that you can use discount cards like GoodRx or SingleCare to compare prices, but you cannot combine them with your insurance for the same prescription. You have to choose one or the other. This means you need to know your insurance cost first. Then, compare it to the cash price. If the cash price is lower, you might be better off paying out of pocket for that specific drug, even if it is covered by your plan. This is a strategy that can save hundreds of dollars a year. The key is to be proactive. Do not wait until the new year to find out that your drug is no longer covered. Make the decision now, while you still have the power to choose.